Phase 1b Trial of Oral DNL343 in ALS Patients Begins Dosing

Phase 1b Trial of Oral DNL343 in ALS Patients Begins Dosing

306227

Phase 1b Trial of Oral DNL343 in ALS Patients Begins Dosing

A Phase 1b clinical trial evaluating the safety and pharmacological profile of DNL343, Denali Therapeutics’ investigational oral therapy, in adults with amyotrophic lateral sclerosis (ALS) has started dosing participants. The study (NCT05006352) is currently recruiting patients at the Centre for Human Drug Research (CHDR) in Leiden, Netherlands. Additional sites are expected to open as well. “Initiation of this Phase 1b study marks a significant milestone in the development of DNL343 for the potential treatment of…

You must be logged in to read/download the full post.